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Abstract: A field study undertaken in Australia compared the antibody responses induced in client-
owned cats that had been vaccinated using two inactivated whole feline leukaemia virus (FeLV)
vaccines, the monovalent vaccine Fel-O-Vax® Lv-K and the polyvalent vaccine Fel-O-Vax® 5. Serum
samples from 428 FeLV-uninfected cats (118 FeLV-vaccinated and 310 FeLV-unvaccinated) were
tested for anti-FeLV neutralising antibodies (NAb) using a live virus neutralisation assay to identify
378 FeLV-unexposed (NAb-negative) and 50 FeLV-exposed (NAb-positive; abortive infections) cats,
following by anti-surface unit (SU) FeLV-A and FeLV-B antibody ELISA testing. An additional
42 FeLV-infected cats (28 presumptively regressively infected, 14 presumptively progressively in-
fected) were also tested for anti-SU antibodies. NAb-positive cats displayed significantly higher
anti-SU antibody ELISA responses compared to NAb-negative cats (p < 0.001). FeLV-unexposed cats
(NAb-negative) that had been vaccinated less than 18 months after a previous FeLV vaccination using
the monovalent vaccine (Fel-O-Vax® Lv-K) displayed higher anti-SU antibody ELISA responses
than a comparable group vaccinated with the polyvalent vaccine (Fel-O-Vax® 5) (p < 0.001 for both
anti-FeLV-A and FeLV-B SU antibody responses). This difference in anti-SU antibody responses
between cats vaccinated with the monovalent or polyvalent vaccine, however, was not observed
in cats that had been naturally exposed to FeLV (NAb-positive) (p = 0.33). It was postulated that
vaccination with Fel-O-Vax® 5 primed the humoral response prior to FeLV exposure, such that
antibody production increased when the animal was challenged, while vaccination with Fel-O-Vax®
Lv-K induced an immediate preparatory antibody response that did not quantitatively increase after
FeLV exposure. These results raise questions about the comparable vaccine efficacy of the different
FeLV vaccine formulations and correlates of protection.
Keywords: Australia; FeLV vaccination; humoral immunity; FeLV infection; vaccine efficacy; veteri-
nary science
1. Introduction
Feline leukaemia virus (FeLV), a member of the Retroviridae family, was first reported
in 1964 following its discovery by Bill Jarrett and colleagues during the investigation
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of a time–space cluster of cats with T-cell lymphoma [1]. Subsequent research reported
persistently viraemic cats with progressive FeLV infections to be 62 times more likely to
develop lymphoma or leukaemia than FeLV-uninfected cats [2,3]. A potential link between
transiently viraemic cats with regressive FeLV infections and lymphoma has also been
suggested [4–6].
In addition to providing an early example of viral oncogenesis, abortive FeLV infec-
tions provide one of the few examples of a retroviral infection from which some animals can
completely recover. In contrast, other retroviruses such as bovine leukaemia virus, feline
immunodeficiency virus (FIV), feline foamy virus, equine infectious anaemia virus, caprine
arthritis encephalitis virus and human immunodeficiency virus-1 (HIV-1), cause life-long
infections [7]. Additionally, FeLV is one of the few retroviruses for which commercial
vaccines exist (in addition to FIV and Jembrana disease in cattle) [8–16]. Consequently, the
analysis of immune responses facilitating complete recovery in FeLV-exposed cats with
abortive infections, and those protecting cats following FeLV vaccination, are important to
assist with current efforts to develop effective vaccines against other retroviruses, such as
HIV-1 [17,18].
Antibody-mediated (humoral) and cell-mediated immunity are both important in
protecting against FeLV infection [8,19]. Following exposure to FeLV, virus-neutralising
antibodies (NAbs) directed predominantly against the surface unit (SU) envelope glycopro-
tein gp70 have been observed in cats with abortive infections, in which FeLV replication
is restricted to oropharyngeal tissues before being cleared [20–22]. Anti-FeLV NAbs have
also been detected in cats with transient viraemia (regressive infections) [19,23–25]. Kittens
fed colostrum from queens that had recovered from natural FeLV infection, and then
subsequently challenged with FeLV, were protected from persistent viraemia (progressive
infection) due to the passive transfer of anti-FeLV NAbs [26]. Cats that become persis-
tently viraemic following FeLV challenge typically develop neither NAb nor high levels of
FeLV-specific cytotoxic lymphocytes, indicative of inadequate humoral and cell-mediated
immune responses, respectively [23–25,27]. FeLV vaccination likely primes the humoral
and cellular immune responses; thus, anti-FeLV NAbs are usually not detectable in FeLV-
vaccinated cats pre-challenge but develop in response to experimental or natural exposure
to FeLV [8,9,11,19,21,27–29].
The aim of this study was to investigate the anti-SU antibody responses of client-
owned cats in Australia that had been vaccinated against FeLV using two commercially
available, inactivated whole-virus (IWV) FeLV vaccines (Fel-O-Vax® Lv-K and Fel-O-
Vax® 5).
2. Materials and Methods
2.1. Study Population
Residual samples from a study investigating FeLV infection in healthy client-owned
cats, which included client-owned cats from 13 veterinary hospitals around Australia [14],
and cats from two rescue facilities in Sydney, New South Wales (NSW) that were sampled
in response to FeLV-associated disease outbreaks [21], were utilised.
Animal ethics approval for the sampling of the client-owned cats was granted by the
University of Sydney Animal Ethics Committee (Approval number N00/1-2013/3/5920),
while the rescue cats were sampled and tested at the request of the facility managers
following the diagnosis of progressive FeLV infections.
2.2. Vaccination History
Vaccination histories were extracted from the medical records of client-owned cats.
FeLV-vaccinated cats had been vaccinated with Fel-O-Vax® Lv-K or Fel-O-Vax® 5 (both
vaccines manufactured by Boehringer Ingelheim, Fort Dodge, IA, USA). Five of the 13
veterinary hospitals from which cats were recruited routinely vaccinated at-risk cats against
FeLV: two hospitals used monovalent Fel-O-Vax® Lv-K and three used polyvalent Fel-O-
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Vax® 5. Pre-vaccination FeLV testing was not performed by any of the hospitals. No rescue
cats had been vaccinated against FeLV.
Fel-O-Vax® Lv-K is an adjuvanted monovalent FeLV vaccine. This vaccine was admin-
istered at the same time as Fel-O-Vax® 3, an adjuvanted polyvalent core vaccine containing
feline parvovirus virus (FPV), feline herpesvirus type-1 (FHV-1) and feline calicivirus (FCV),
but at a different anatomical site. Fel-O-Vax® 5 (also sold as Fel-O-Vax® Lv-K IV in North
America by Elanco Animal Health, Greenfield, IN, USA) is an adjuvanted pentavalent
vaccine that contains FeLV, FPV, FHV-1, FCV and Chlamydia felis. The FeLV component
of both Fel-O-Vax® Lv-K and Fel-O-Vax® 5 is produced as an IWV vaccine from a single
subtype isolate (FeLV-A/61E), by the same manufacturer, in the same facility. The antigen
potency specifications (minimum and maximum release titres) for FeLV are the same for
both Fel-O-Vax® Lv-K and Fel-O-Vax® 5 (Adam Heeley, Technical Services Veterinarian,
Boehringer Ingelheim Animal Health Australia per comm).
When multiple vaccines were administered concurrently, they were given as separate
injections, in different syringes, at different sites. All vaccines were injected subcutaneously
into the dorsal interscapular area, except for Fel-O-Vax® Lv-K, which was injected into the
right flank fold. In this study, “on-time” vaccination was defined as a primary course of two
vaccines given one month apart followed by annual re-vaccination as per manufacturer’s
guidelines, with the last FeLV vaccine being administered within 18 months of sampling.
Although Fel-O-Vax® Lv-K and Fel-O-Vax® 5 are registered as annual vaccines in Australia,
the duration of immunity for FeLV vaccines has been shown to exceed 12 months [10,30–34].
The term “overdue” vaccination was used to define cats for which the last FeLV vaccine
had been given more than 18 months prior to sampling.
2.3. Determination of FeLV Exposure/Infection Status
A combination of FeLV p27 capsid antigen testing and FeLV proviral real-time poly-
merase chain reaction (qPCR) testing was used to classify cats as FeLV-uninfected or
FeLV-infected, using accepted definitions [35]. FeLV p27 testing of whole blood was
performed using three commercially available FeLV point-of-care (PoC) antigen test kits
(SNAP Combo®, IDEXX Laboratories, Westbrook, ME, USA; Witness®, Zoetis Animal
Health, Lyon, France; and Anigen Rapid®, BioNote, Gyeonggi-do, Korea). FeLV proviral
qPCR testing was performed in-house according to a published protocol, using primers
designed to amplify a section of the unique region (U3) of the long terminal repeat (LTR) of
the three main subtypes of FeLV [35,36].
Cats testing p27-negative/qPCR-negative were considered FeLV-uninfected, and NAb
results were used to further categorise these cats as FeLV-unexposed (NAb-negative) or
FeLV-exposed (NAb-positive; abortive infections). FeLV-vaccinated cats testing NAb-
positive were classified as abortive infections, since FeLV-vaccinated cats do not produce
NAbs prior to exposure to FeLV [8,9,11,19,21,27–29]. Cats testing p27-negative/qPCR-
positive were considered presumptively regressively infected, while cats testing p27-
positive/qPCR-positive were considered presumptively progressively infected (Figure 1).
FeLV infection status was considered “presumptive”, since testing had been performed
at a single time point and therefore it was not possible to confirm whether viraemia (as
determined by p27 positivity) was transient or persistent.
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a white outline and a question mark to represent a possible predisposition to developing lymphoma; 
and presumptively progressively infected cats are represented as a black cat with a white outline 
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“presumptively” infected since testing was only performed at a single time point. NAb = 
neutralising antibody, qPCR = real-time polymerase chain reaction. 
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to the virus control wells incubated without plasma. A NAb titre of 4 was considered 
weakly NAb-positive, while 32 or greater was considered a strong NAb-positive value. 
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Anti-SU antibody ELISA testing was performed to assess humoral response to FeLV 
vaccination, since FeLV-vaccinated cats have been shown to produce pre-challenge 
antibodies against whole FeLV and p45 (the non-glycosylated form of gp70) quantifiable 
by ELISA [37], whereas FeLV-vaccinated cats do not produce NAb without FeLV 
exposure [8,9,11,19,21,27–29]. Plasma samples were tested for anti-SU antibodies, using 
both Fc-tagged FeLV-A SU and Fc-tagged FeLV-B SU as capture antigens, to ensure a 
comprehensive analysis of antibody responses against FeLV SU and to maximise test 
sensitivity [38]. The FeLV-B SU antibody response was interpreted as an antibody 
response to an epitope shared between FeLV-A and FeLV-B SU. 
Positive and negative controls were included on each test plate. The positive control 
was a pooled sample of plasma from specific pathogen-free (SPF) cats that had recovered 
from experimental FeLV infection and tested strongly positive for anti-FeLV NAbs. The 
negative control was a pooled sample of plasma from SPF cats that had negligible 
reactivity to FeLV SU by immunoblot. Normalised optical density (NOD) values were 
determined using the formula NOD = [(Sample OD—Negative control OD)/(Positive 
control OD—Negative control OD)]. Samples were tested in triplicate and tests were 
Figure 1. Algorithm used for classifying the FeLV exposure and infection status of cats recruited
for the current study (grey cat with black outline). Cats unexposed to FeLV are represented as a
white cat with a black outline; FeLV-uninfected cats that had been exposed to FeLV (NAb-positive;
abortive infections) are represented as a white cat with a black outline and surrounded by FeLV,
to demonstrate their robust immune response to clear early FeLV infection and protect them from
further FeLV challenge; presu ptively regressively infected cats are represented as a grey cat with a
hite tli t represe t a po sible predisposition to developing lymphoma;
and presumptively r t cats are represented as a black cat with a white outline and
a tombstone to represent their poor prognosis. FeLV-infected cats were classified as “presumptively”
infected since testing was only performed at a single time point. NAb = neutralising antibody,
qPCR = real-time polymerase chain reaction.
2.4. FeLV NAb Testing
NAb detected using a focus reduction est [29]. Briefly, QN10 cells were incubated
overnight in 12-well plates (4 × 104 cells/mL) b fore the addition of 4 × 102 FFU/mL of
eLV-A/Glasgow-1 that had been incu ated for 2 h with an equal volume of two-fold,
serial ilutions of plasma samples (1/4, 1/8, 1/ 6 and 1/32). Residual infectivity was
measured in quadruplicate wells. NAb titres were record d as the reciprocals of the plasma
dilutions that visibly reduced the number of focus f rming units by 75% compared to the
virus control wells incubated without plasma. A NAb titre of 4 was considered weakly
NAb-positive, while 32 or greater was considered a strong NAb-positive value.
2.5. FeLV Anti-SU Antibody ELISA Testing
Anti-SU antibody ELISA testing was performed to assess humoral response to FeLV
vaccination, since FeLV-vaccinated cats have been shown to produce pre-challenge an-
tibodies against whole FeLV and p45 (the non-glycosylated form of gp70) quantifiable
by ELISA [37], whereas FeLV-vaccinated cats do not produce NAb without FeLV expo-
sure [8,9,11,19,21,27–29]. Plasma samples were tested for anti-SU antibodies, using both
Fc-tagged FeLV-A SU and Fc-tagged FeLV-B SU as capture antigens, to ensure a comprehen-
sive analysis of antibody responses against FeLV SU and to maximise test sensitivity [38].
The FeLV-B SU antibody response was interpreted as an antibody response to an epitope
shared between FeLV-A and FeLV-B SU.
Positive and negative controls were included on each test plate. The positive control
was a pooled sample of plasma from specific pathogen-free (SPF) cats that had recovered
from experimental FeLV infection and tested strongly positive for anti-FeLV NAbs. The
negative control was a pooled sample of plasma from SPF cats that had negligible reactivity
to FeLV SU by immunoblot. Normalised optical density (NOD) values were determined
using the formula NOD = [(Sample OD—Negative control OD)/(Positive control OD—
Negative control OD)]. Samples were tested in triplicate and tests were repeated if the
standard deviation was >0.1. Anti-SU ELISA results were not categorised as “positive” or
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“negative”; rather, the range of antibody responses against SU were compared among the
cats tested.
2.6. Determination of FIV Status
Cats were considered FIV-infected if they tested positive for FIV antibodies using
two commercially available FIV PoC antibody test kits (Witness®, Zoetis Animal Health,
Lyon, France; and Anigen Rapid®, BioNote, Gyeonggi-do, Korea), which can be used to
differentiate FIV-infected and FIV-vaccinated cats [38]. In addition, client-owned cats were
tested for FIV proviral DNA using a commercially available qPCR assay (FIV RealPCRTM,
IDEXX Laboratories, East Brisbane, QLD, Australia), and virus isolation (VI) was performed
in rare, discrepant cases (Yamamoto Laboratory, The University of Florida, Gainesville, FL,
USA; and Veterinary Diagnostic Services, The University of Glasgow, Scotland, UK) [39,40].
2.7. Statistical Analysis
Numerical analyses were performed using the statistical software Genstat 18th Edition
(VSN International, Hemel Hempstead, UK) and R Version 3.6.2 (The R Foundation,
Vienna, Austria). Ordinal logistic regression (OLR) testing was used to compare sex
and breed compositions between groups. A Shapiro–Wilk test was used to assess data
for normality. Normally distributed data (cat ages) were analysed using means and
two-sample t-testing, while non-normal data (anti-SU NOD values) were analysed using
medians, Mann–Whitney U-testing (paired samples) and restricted maximum likelihood
(REML) modelling (multiple groups). Fisher’s exact testing was used to compare binomial
outcomes. Statistical significance was considered when p < 0.05.
3. Results
3.1. Sample Population (n = 470)
Residual samples from 470 cats were available for testing (403 client-owned cats, 67 res-
cue cats) [21]. The signalment details for the entire feline cohort have been described [21].
For the current study, the age, sex and breed of the FeLV-vaccinated/FeLV-uninfected
(n = 118) and FeLV-unvaccinated/FeLV-uninfected (n = 310) groups were similar (p = 0.36,
0.95 and 0.25, respectively; 2-sample t-testing for age, OLR testing for sex and breed). The
age, sex and breed of Fel-O-Vax® Lv-K vaccinated on-time/FeLV-unexposed cats (n = 10)
and Fel-O-Vax® 5 vaccinated on-time/FeLV-unexposed cats (n = 40) were similar (p = 0.94,
0.51 and 1.00, respectively), as were the age, sex and breed of Fel-O-Vax® Lv-K vaccinated
on-time/FeLV-exposed cats (n = 13) and Fel-O-Vax® 5 vaccinated on-time/FeLV-exposed
cats (n = 26) (p = 0.56, 0.51 and 1.00, respectively; 2-sample t-testing for age, OLR testing
for sex and breed for both comparisons). FeLV-unexposed cats vaccinated on-time with
Fel-O-Vax® Lv-K had been re-vaccinated annually 1–7 times, and FeLV-unexposed cats
vaccinated on-time with Fel-O-Vax® 5 had been re-vaccinated annually 0–10 times; the
median number of annual FeLV vaccinations of both groups was four.
The categorisation of 428 FeLV-uninfected cats and 42 FeLV-infected cats according to
FeLV vaccination history and FeLV infection status is shown in Table 1. Four FeLV-infected
cats (three presumptively regressive, one presumptively progressive) had been vaccinated
against FeLV, although their FeLV infection status prior to primary vaccination had not
been determined.
In total, 33 cats were FIV-infected, including four cats co-infected with FIV and FeLV
(2 presumptively progressive FeLV infections with FeLV cycle threshold (CT) values of 16.8
and 21.3, respectively; 2 presumptively regressive FeLV infections with CT values of 31.2
and 37.2, respectively).
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Table 1. Summary of FeLV infection status and FeLV vaccination history of the cats in the current study (n = 470). On-time
vaccination referred to the previous vaccination being given within the past 18 months, while overdue vaccination referred
to the last vaccination being given more than 18 months previously. FeLV-uninfected/FeLV-unexposed cats that were
overdue for vaccination were excluded from all analyses, while FeLV-uninfected/FeLV-exposed cats (abortive infections)
overdue for vaccination were retained. None of the four FeLV-vaccinated/FeLV-infected cats had been tested for FeLV
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infections (n = 28)
(p27-negative,
qPCR-positive)
25 1 1 1 2 0 1 3
Presumptively progressive
infections (n = 14)
(p27-positive,
qPCR-positive)
13 0 1 4 0 0
1 Vaccinated with Fel-O-Vax® Lv-K, three months prior to sampling. 2 Vaccinated with Fel-O-Vax® 5, nine months prior to sampling.
3 Vaccinated with Fel-O-Vax® 5, 136 months prior to sampling. 4 Vaccinated with Fel-O-Vax® 5, two months prior to sampling.
3.2. FeLV NAb Testing
Seventy-eight samples tested NAb-positive, including 50 FeLV-uninfected cats (abortive
infections; 39 cats FeLV-vaccinated on-time, four overdue for FeLV vaccination and seven
FeLV-unvaccinated cats), 26 presumptively regressive infections and two presumptively
progressive infections (that likely represented one early regressive infection that was still
antigenaemic and one focal infection [21]). The remaining 392 samples tested NAb-negative.
Presumptively regressive infections tended to test NAb-positive whereas presumptively
progressive infections tended to test NAb-negative (26/28 (93%) vs. 2/14 (14%); p < 0.0001;
Fisher’s exact test) (Table 1).
A higher proportion of FeLV-vaccinated/FeLV-uninfected cats tested NAb-positive
compared to FeLV-unvaccinated/FeLV-uninfected cats (43/118 (36%) vs. 7/310 (2%);
p < 0.0001; Fisher’s exact test). There was no difference in exposure rate between the
monovalent vaccine group (Fel-O-Vax® Lv-K) and the polyvalent vaccine group (Fel-
O-Vax® 5), irrespective of whether cats overdue for vaccination or vaccinated/infected
cats were included, suggesting a similar risk of FeLV exposure for both groups (10/23
(43%) vs. 40/66 (61%) for on-time vaccination, 14/28 (50%) vs. 61/90 (68%) including on-
time/overdue vaccination, and 14/29 (48%) vs. 61/93 (66%) including vaccinated/infected
cats; p = 0.22, 0.12 and 0.13, respectively; Fisher’s exact tests). Both monovalent and
polyvalent vaccinated/exposed cats (abortive infections) displayed a range of NAb titres
(Table 2). There was no significant difference between the monovalent and polyvalent
vaccines in vaccinated/exposed cats according to reciprocal NAb titre (4—p = 0.59; 8—
p = 0.94; 16—p = 0.96; ≥32—p = 0.37; 2-sample binomial tests).
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Table 2. Summary of NAb results in vaccinated/exposed cats (abortive infections), arranged by
vaccination type and reciprocal titre. A NAb titre of 4 was considered weakly NAb-positive while a
NAb titre of 32 or greater was considered strongly NAb-positive. Cats overdue for vaccination were
included (one vaccinated with Fel-O-Vax® Lv-K, three vaccinated with Fel-O-Vax® 5). NAb = neu-
tralising antibody.
NAb Result
4 8 16 ≥32
Monovalent vaccine (Fel-O-Vax® Lv-K; n = 14) 5 (36%) 5 (36%) 3 (21%) 1 (7%)
Polyvalent vaccine (Fel-O-Vax® 5; n = 29) 8 (28%) 10 (34%) 6 (21%) 5 (17%)
3.3. FeLV Anti-SU Antibody ELISA Testing by NAb Result
Anti-SU antibody ELISA levels for NAb-positive cats (n = 78) were significantly higher
than for NAb-negative cats (n = 392) (2.4 vs. 0.9 for FeLV-A, 2.2 vs. 1.2 for FeLV-B; p < 0.001
for both; Mann–Whitney U-tests). Anti-SU antibody levels against FeLV-A for strongly
neutralising samples (≥32) were significantly higher than other NAb-positive samples
grouped according to reciprocal titre (i.e., 4, 8 and 16; NOD values were 1.9, 2.1, 2.3
and 2.6 for 4, 8, 16 and ≥32, respectively) (p = 0.03; REML testing). Anti-SU antibody
ELISA levels against FeLV-B were not significantly different between NAb-positive samples
grouped according to reciprocal titre (NOD values were 2.3, 2.1, 2.3 and 2.2 for 4, 8, 16 and
≥32, respectively) (p = 0.32; REML testing). All NAb-positive groups, when considered
individually (i.e., 4, 8, 16 and 32), were significantly higher against both FeLV-A and FeLV-B
SU than NAb-negative samples (p < 0.001; least significant difference testing) (Figure 2).
The positive control sample included on each plate had a mean absorbance of 2.6 and
the negative control had a mean OD of 0.5.
3.4. FeLV Anti-SU Antibody ELISA Testing in Unvaccinated Cats and Abortive Infections
The anti-SU antibody ELISA levels against FeLV-A of unvaccinated/unexposed cats
(n = 303; considered to be the field control group) were significantly lower than those of
presumptively progressively infected cats (n = 14) (0.9 vs. 1.1, p = 0.012; Mann–Whitney
U-test), but unvaccinated/unexposed cats had significantly higher anti-SU antibody ELISA
levels against FeLV-B than presumptively progressively infected cats (1.1 vs. 0.7, p = 0.009;
Mann–Whitney U-test). A wide range of anti-SU ELISA values was observed in this field
control group (0.07–2.9 against FeLV-A, 0.1–2.5 against FeLV-B). Presumptively regressive
infections (n = 28) had significantly higher anti-SU antibody ELISA levels (2.5/1.9 against
FeLV-A/FeLV-B) than both unvaccinated/unexposed cats and presumptively progres-
sively infected cats (p < 0.001 for both; Mann–Whitney U-tests). Anti-SU antibody ELISA
responses were similar between presumptively regressive infections and pooled vacci-
nated/unvaccinated abortive infections (n = 50; 2.2/2.3 against FeLV-A/FeLV-B) (p = 0.10
for FeLV-A, p = 0.62 for FeLV-B; Mann–Whitney U-tests; Figure 3). Excluding anti-SU
antibody results from four infected cats (three regressive, one progressive) that were vacci-
nated, to exclude possible confounding effects of vaccination and infection on antibody
production, had no effect on the findings.
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Figure 4. Comparison of anti-SU antibody ELISA responses to examine the effect of FeLV vaccination and natural exposure
to FeLV following vaccination ((A) anti-FeLV-A SU antibody ELISA results, (B) anti-FeLV-B SU antibody ELISA results).
The field control group consisted of unvaccinated and unexposed cats (n = 3 is included to provide bas line. Ten
unexposed cats had been vaccinated on-time with Fel-O-Vax® Lv-K and 40 unexposed cats had been vaccinated on-time
with Fel-O-Vax® 5. In total, 43 vaccinated/uninfected cats had been exposed to FeLV (abortive infections), including
14 cats vaccinated with Fel-O-Vax® Lv-K and 29 cats vaccinated with Fel-O-Vax® 5. Statistically significant differences in
median NOD values between vaccinate groups after exposure re shown. The monovalent vaccine (Fel-O-Vax® Lv-K)
induced significantly higher antibody levels in unexposed cats against both FeLV-A and FeLV-B SU than the polyvalent
vaccine (Fel-O-Vax® 5) (p < 0.001 for both; Mann–Whitney U-tests). Cats vaccinated with the polyvalent Fel-O-Vax® 5
vaccine and exposed to FeLV displayed a booster effect of natural FeLV exposure (p < 0.001 for both FeLV-A and FeLV-B SU;
Mann–Whi ney U-t sts); ats vaccinat d with e onovalent Fel-O-Vax® Lv-K vacci e and exposed to FeLV displayed
no such booster effect (p = 0.33 for FeLV-A and p = 0.82 for FeLV-B; Mann–Whitney U-tests). Data points are plotted
as open circles, centre lines show the medians, box limits indicate the 25th and 75th percentiles, and whiskers extend
1.5 times the interquartile range from the 25th and 75th percentiles. NOD = normalised optical density, SU = surface unit,
LvK = Fel-O-Vax® Lv-K, F5 = Fel-O-Vax® 5.
Viruses 2021, 13, 240 11 of 18
3.5. FeLV Anti-SU Antibody ELISA Testing in Vaccinated Cats
The anti-SU antibody ELISA levels against FeLV-A of polyvalent FeLV-vaccinated
(Fel-O-Vax® 5)/unexposed cats (n = 40) were not significantly different from unvac-
cinated/unexposed cats (n = 303) (0.9 vs. 0.9; p = 0.18; Mann–Whitney U-test), but
FeLV-vaccinated (Fel-O-Vax® 5)/unexposed cats had significantly higher anti-SU anti-
body responses against FeLV-B compared to unvaccinated/unexposed cats (1.5 vs. 1.1);
p = 0.002; Mann–Whitney U-test). Anti-SU antibody ELISA levels of monovalent FeLV-
vaccinated (Fel-O-Vax® Lv-K)/unexposed cats (n = 10) were significantly higher than
unvaccinated/unexposed cats (n = 303) for both FeLV-A and FeLV-B (2.0 vs. 0.9 and 2.3 vs.
1.1, respectively; p < 0.001 for both; Mann–Whitney U-tests) (Figure 4).
3.6. Comparing FeLV Anti-SU Antibody Responses between Fel-O-Vax® Lv-K and Fel-O-Vax® 5
When unexposed cats vaccinated on-time with the two FeLV vaccines were compared,
the monovalent vaccine (Fel-O-Vax® Lv-K) induced significantly higher antibody levels
against both FeLV-A and FeLV-B SU than the polyvalent vaccine (Fel-O-Vax® 5) (2.0 vs.
0.9 and 2.3 vs. 1.5; p < 0.001 for both; Mann–Whitney U-tests) (Figure 4). These findings
were unchanged if the definition of on-time vaccination was changed from 18 months to
12 months since last FeLV vaccination.
Cats vaccinated with the polyvalent Fel-O-Vax® 5 vaccine and exposed to FeLV (n = 29,
including three cats overdue for vaccination) had significantly higher anti-SU antibody
ELISA levels against both FeLV-A and FeLV-B compared to cats vaccinated on-time with
Fel-O-Vax® 5 and unexposed (n = 40), consistent with a booster effect of natural FeLV
exposure (2.1 vs. 0.9 for FeLV-A and 2.3 vs. 1.5 for FeLV-B; p < 0.001 for both; Mann–
Whitney U-tests). No booster effect was observed in cats vaccinated with the monovalent
Fel-O-Vax® Lv-K and exposed to FeLV (n = 14, including one cat overdue for vaccination)
compared to cats vaccinated on-time with Fel-O-Vax® Lv-K and unexposed (n = 10) (2.2
vs. 2.0 for FeLV-A and 2.3 vs. 2.3 for FeLV-B; p = 0.33 and 0.82; Mann–Whitney U-tests)
(Figure 4).
When vaccinated/exposed cats were compared, there was no significant difference in
antibody response against either FeLV-A or FeLV-B SU between cats vaccinated with the
two different FeLV vaccines (p = 0.65 and 0.33, respectively; Mann–Whitney U-tests).
Unfortunately, group sizes were too small to compare vaccinated/unexposed and vac-
cinated/exposed cats based on the number of annual FeLV re-vaccinations administered.
4. Discussion
In this study, anti-FeLV SU antibody responses were measured by ELISA, comparing
the results between FeLV-vaccinated and FeLV-unvaccinated cats given core vaccines
concurrently under natural conditions. Surprisingly, despite the two IWV FeLV vaccines
being derived from the same cell line and strain of FeLV (FeLV-A/61E), using the same
adjuvant formulation and being produced by a single manufacturer in the same facility [41],
a quantitatively different humoral response was observed.
Vaccination using the monovalent FeLV vaccine (Fel-O-Vax® Lv-K, given concurrently
with Fel-O-Vax® 3) induced significantly higher anti-SU antibody levels in FeLV-unexposed
cats against both FeLV-A and FeLV-B compared to vaccination using a polyvalent vaccine
that included a FeLV component (Fel-O-Vax® 5). Following natural exposure to FeLV, how-
ever, antibody responses to the different vaccines were similar. While vaccination with the
polyvalent Fel-O-Vax® 5 reproduced the response reported from experimental studies, in
which FeLV vaccination led to minimal antibody production but primed the cat’s humoral
immune system in case of FeLV exposure [19], vaccination with the monovalent Fel-O-Vax®
Lv-K resulted in a robust humoral response irrespective of FeLV exposure. Similarly, a
strong humoral immune response following vaccination (and prior to experimental FeLV
challenge) with a recombinant p45 FeLV vaccine (Leucogen®) has been observed, using an
ELISA to measure anti-p45 antibodies [42].
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This is the first time that a difference in antibody response between cats vaccinated
with Fel-O-Vax® Lv-K and Fel-O-Vax® 5 has been reported. Previously, most Fel-O-Vax®
vaccine studies have only considered one of the two vaccine formulations at a time and
have been primarily concerned with vaccine efficacy as determined by the presence or
absence of antigenaemia or viraemia after challenge (Table 3). Only two groups to date have
concurrently reported the efficacies of the monovalent and polyvalent Fel-O-Vax® FeLV
vaccines, but neither measured anti-FeLV antibody levels following vaccination or FeLV
challenge [30,41,43]. The effect of FIV infection on the anti-SU antibody response following
FeLV vaccination in the current study could not be examined because of insufficient sample
sizes, although it was reported that healthy experimentally FIV-infected cats were able
to mount a sufficient humoral immune response to vaccination with a recombinant FeLV
vaccine in the early phase of FIV infection [42].
Any anti-FeLV SU antibody result should be considered alongside results from p27
antigen and proviral PCR testing, particularly when testing has only been performed at a
single time point [44]. As predicted, presumptively progressively infected cats in the current
study had low anti-SU antibody levels, indicative of poor humoral (and presumably cell-
mediated) immune responses despite ongoing viraemia (antigenaemia). There was a wide
range of anti-SU responses detected by ELISA for the field control group (unvaccinated and
unexposed); we suspect that this spread of results could have reflected anti-SU antibodies
that were detected by ELISA but did not neutralise the virus used in the NAb assay, since
it was demonstrated previously that some FeLV-infected cats produce antibodies that do
not contribute to virus neutralisation [45]. It is likely that the field control group contained
some cats that had recovered from FeLV exposure after developing protective cellular
immunity mediated by FeLV-specific cytotoxic T lymphocytes, in the absence of NAb,
while developing antibodies that were detectable by ELISA [19,23,24]. Presumptively
regressively infected cats displayed higher anti-SU antibody levels than presumptively
progressively infected cats and the field control group, and similar levels to the antibody
responses in uninfected/exposed cats (abortive infections), providing evidence of strong
and effective humoral immune responses in naturally infected cats with regressive FeLV
infections [21,22,28,44,46]. This conclusion was also supported by the higher proportion of
presumptively regressively infected cats that tested positive for anti-FeLV NAbs, compared
to only a small number of presumptively progressively infected cats.
The reason for the difference in antibody response observed between cats vaccinated
with the monovalent FeLV and polyvalent FeLV vaccine is not known. A saturation
phenomenon with the anti-SU antibody ELISA, that might have limited higher NOD
values (e.g., for cats vaccinated with Fel-O-Vax® Lv-K and then naturally exposed to FeLV),
was considered unlikely on the basis of internal testing that demonstrated a concentration
dependent decrease in absorbance levels, even with a range of starting sample dilutions.
This finding contrasts with a study that compared the immunogenicity of a recombinant
FeLV p45 vaccine given as a monovalent or polyvalent formulation (Nobivac® FeLV vs.
lyophilised Nobivac® Forcat reconstituted in one dose of Nobivac® FeLV), reporting that
both vaccinations induced comparable antibody levels against FeLV as measured by an
anti-p45 antibody ELISA [47]. One possible explanation for the unexpected results from the
current study is that the route of vaccine administration impacted the antibody response,
since Fel-O-Vax® Lv-K was injected into the right flank fold and Fel-O-Vax® 5 was injected
into the dorsal interscapular region. In humans, a reduced seroconversion rate (up to
17-fold) was reported when an intramuscular hepatitis B vaccine was administered in the
buttock rather than the arm, with delayed vaccine antigen release, or a lower number of
macrophages, T and B lymphocytes in the injected area, hypothesised to be responsible
for the difference in antibody response [48]. In rats, the highest antibody levels following
vaccination with a commercial core canine vaccine were found in animals vaccinated
subcutaneously in the houhai acupuncture site (the dorsal midline between the anus and
tail base), and the lowest antibody levels were in animals vaccinated subcutaneously in the
back at the level of the last thoracic vertebra on the dorsal midline [49]. Additional imaging
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investigations by the same researchers suggested that the enhanced humoral response
observed in rats was as a result of increased lymphocyte activation and drainage in the
houhai acupoint compared to the dorsal interscapular area [50]. To the best of the authors’
knowledge, no studies have investigated differences in anti-FeLV antibody responses in
cats associated with the site of vaccination, in part because vaccine licensing studies usually
involve administering vaccinations subcutaneously into the interscapular region [33].
The European Advisory Board on Cat Diseases (ABCD) guidelines on feline injection-
site sarcoma recommend that veterinarians should avoid administering any vaccinations
subcutaneously into the interscapular region. Vaccination in the distal limb or tail is
recommended as surgery is more likely to be curative if a sarcoma develops at one of those
sites compared to the interscapular area [51,52].
A second possible explanation for this unexpected finding is that an adjuvant effect
was observed, with approximately two times the volume of adjuvant inducing higher
anti-FeLV antibody responses (total adjuvant volume when Fel-O-Vax® 3 and Fel-O-Vax®
Lv-K given concurrently was 2 mL vs. 1 mL with Fel-O-Vax® 5). A previous investigation
of Fel-O-Vax® Lv-K efficacy reported a clear association between adjuvant concentration
and vaccine efficacy [41]. Furthermore, in this study, 8/10 FeLV-unexposed cats vaccinated
on-time with Fel-O-Vax® Lv-K and Fel-O-Vax® 3 were also concurrently vaccinated against
FIV (Fel-O-Vax® FIV; Boehringer Ingelheim, Fort Dodge, IA, USA), making a total adjuvant
volume administered of 3 mL. Conversely, no difference was observed between FeLV-
unexposed cats concurrently vaccinated with Fel-O-Vax® 5 and Fel-O-Vax® FIV (i.e., total
adjuvant volume 2 mL) and cats vaccinated with Fel-O-Vax® 5 only (i.e., adjuvant volume
1 mL). The sample size was too small to compare the antibody responses of Fel-O-Vax®
Lv-K vaccinated cats with and without the administration of Fel-O-Vax® FIV to examine
the effect of adjuvant volume in these cats. To further explore the possibility of an adjuvant
volume effect, it would be useful to measure antibody responses against FPV, FHV-1
and FCV in the different FeLV-vaccinated groups and to determine whether an enhanced
humoral immune response was a generalised phenomenon.
A third possible explanation for the difference in antibody responses between the
monovalent and polyvalent FeLV vaccine may have been a “batch effect”. Different batches
of FeLV vaccines are known to vary within a range of approved potency values that have
been demonstrated to be safe and efficacious. It is possible, especially given the low rate of
FeLV vaccination in Australia, that the two veterinary hospitals using Fel-O-Vax® Lv-K
(located approximately 5 km apart, owned by the same veterinarian, but run separately
including stock ordering) used FeLV vaccines from the same highly immunogenic batch
during the three-year study period. Unfortunately, vaccine batch numbers were not
recorded in the medical records.
Viruses 2021, 13, 240 14 of 18
Table 3. Summary of vaccine efficacy studies for Fel-O-Vax® Lv-K and Fel-O-Vax® 5 (marketed as Fel-O-Vax® Lv-K IV in the USA). Preventative fraction is defined as ([percentage
persistent viraemia in controls]—[percentage persistent viraemia in vaccinates]/percentage persistent viraemia in controls ×100). Since both Fel-O-Vax® Lv-K and Fel-O-Vax® 5 are
inactivated whole-virus vaccines derived from the same seed virus (FeLV-A/61E), challenge with FeLV-A/61E virus is considered homologous FeLV challenge, while challenge with a
strain other than FeLV-A/61E is considered heterologous FeLV challenge. IP = intraperitoneal, ON = oronasal, IN = intranasal, SC = subcutaneous.
Reference Vaccine How Vaccine Given Challenge Information Number of Cats Infected PreventativeFractionFeLV Strain Route Vaccinates Controls
Torres et al. (2010)
[11] Fel-O-Vax
® Lv-K Not stated FeLV-A/61E IP (4 months after lastvaccination) 0/8 7/8 100%
Grosenbaugh et al.
(2006) [53] Fel-O-Vax
® Lv-K SC, caudolateralthigh FeLV-A/61E




Torres et al. (2005)
[27] Fel-O-Vax
® Lv-K SC, location notstated FeLV-A/61E
ON (3 weeks after last
vaccination) 1/10 7/10 86%
Grosenbaugh et al.
(2004) [54] Fel-O-Vax
® Lv-K SC, caudolateralthigh FeLV-A/61E




Hoover et al. (1996)
[30] Fel-O-Vax
® Lv-K Not stated FeLV-A/61E Not stated 13% 1 92% 1 86% 1
Legendre et al. (1991)
[43] Fel-O-Vax
® Lv-K SC in the flank
At least four different strains of
FeLV-A (two laboratory strains
and at least two field strains)
In-contact (2 weeks after last
vaccination, for 31 weeks) 0/12 7/11 100%
Sebring et al. (1991)
[41] Fel-O-Vax
® Lv-K Not stated Not stated
IP (2 weeks after last
vaccination), then in-contact
with challenged controls for
72 days)
4/94 57/62 95% 2
Hofmann-Lehmann




stated FeLV subtype A/Glasgow-1
IP (4 weeks after last
vaccination) 5/10 9/10 44%
Hoover et al. (1996)
[30]
Fel-O-Vax® Lv-K IV
(Fel-O-Vax® 5) SC (not stated where) FeLV-A/61E
IN (one year after last
vaccination) 0/5 10/10 100%
3
Sebring et al. (1991)
[41]
Fel-O-Vax® Lv-K IV
(Fel-O-Vax® 5) SC in the flank
At least four different strains of
FeLV-A (two laboratory strains
and at least two field strains)
In-contact (2 weeks after last
vaccination, for 31 weeks) 0/11 7/11 100%
4
1 Exact study numbers were not reported in the manuscript. A total of 150 specific pathogen-free cats were tested. The primary author was contacted and asked for more detail about the site of vaccination, group
numbers and challenge route; unfortunately, the data were no longer available. 2 Results pooled from four different studies. The first two studies reported in this paper are not included in the table. The first
study involved intramuscular vaccination (0/5 vaccinates became FeLV-infected following IP challenge two weeks after the second vaccination, 4/7 control cats became FeLV-infected). The second study
involved varying doses of adjuvant in the vaccine to help determine the optimal vaccine constitution. 3 Five additional cats were vaccinated intramuscularly and are not included in the table. None of these five
cats became FeLV-infected. 4 Study performed by Legendre et al. (1991) [43], reported by Sebring et al. (1991) [41].
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The phenomenon of “antigenic competition” was also considered as a potential ex-
planation for the weaker antibody response that was observed in FeLV-unexposed cats
vaccinated with the polyvalent FeLV vaccine compared to the monovalent FeLV vaccine.
Antigenic competition has been reported in sheep vaccinated against the foot rot pathogen
Dichelobacter nodosus. With this example, however, interference was associated with im-
munologically related pilus antigens, and a high level of protection with the polyvalent
vaccine against all nine antigens was still achieved [55]. We hypothesise that a competitive
effect would not be anticipated in a polyvalent vaccine such as Fel-O-Vax® 5 that contains
five antigenically distinct organisms [56]. Furthermore, Fel-O-Vax® Lv-K vaccinated cats
also received a killed-adjuvanted trivalent core vaccine (Fel-O-Vax® 3) concurrently, but at
a different site. Although antigenic competition is theoretically more likely to occur with
Fel-O-Vax® 5 than concurrent Fel-O-Vax® 3/Fel-O-Vax® Lv-K administration, due to the
local component of antigenic competition, there is no published evidence that suggests
that administering multiple antigens mixed in the same syringe (e.g., Fel-O-Vax® 5) de-
creases the antibody response in vaccinated cats. It seems conceivable, however, that the
pronounced difference in humoral immunogenicity observed in the present study with the
administration of two different vaccine formulations, both containing the same FeLV IWV
antigen potency, could have been the result of the monovalent vaccine (Fel-O-Vax® Lv-K)
being administered to a different area of the cat (right flank fold) and a different draining
lymph node to the other vaccine antigens.
Further research is required, testing larger cohorts of cats, to determine if the
observed difference in antibody response between cats vaccinated using Fel-O-Vax®
Lv-K and Fel-O-Vax® 5 is correlated with a difference in protection from natural FeLV
challenge. Since FeLV exposure/infection status had not been ascertained prior to
FeLV vaccination in any cats, including for the four FeLV-vaccinated/FeLV-infected
cats (three regressive, one progressive), due to the retrospective nature of the current
study, inferences could not be made about FeLV vaccine effectiveness in the field. To
date, only laboratory-based studies involving SPF cats, rather than field-based vaccine
efficacy studies, have been performed to report the preventative fractions of Fel-O-Vax®
Lv-K and Fel-O-Vax® 5, involving different challenge viruses and routes of inoculum
administration (Table 3) [11,27,28,30,41,43,53,54]. In one of only two studies to directly
compare the efficacy of Fel-O-Vax® Lv-K and Fel-O-Vax® Lv-K IV (identical to Fel-O-
Vax® 5), Legendre et al. (1991) (with results reported in Sebring et al. 1991) demonstrated
that no kittens in either group, vaccinated subcutaneously in the flank region, became
progressively infected, and both FeLV vaccines demonstrated preventative fractions of
100% [41,43]. The second study to examine both vaccine formulations reported efficacies
of 86% and 100% for Fel-O-Vax® Lv-K and Fel-O-Vax® Lv-K IV, respectively, but did not
perform any statistical analysis to assess the possible significance of this difference [30].
The efficacies of FeLV vaccines other than the Fel-O-Vax® range, administered as
either monovalent or polyvalent formulations, have been shown to be comparable. For
example, in a study to determine the efficacy of Versifel® FeLV (Zoetis Animal Health; an
IWV vaccine containing FeLV-A, FeLV-B and FeLV-C), administered at the same time as
a modified live-virus (MLV) trivalent core vaccine, no difference in FeLV vaccine efficacy
was observed when the two vaccines were given concurrently (the FeLV component was
injected subcutaneously at the base of the neck and the MLV component was injected
subcutaneously in the left thoracic wall) compared to simultaneous administration (the
MLV component was reconstituted using the FeLV vaccine and the entire contents were
administered subcutaneously at the base of the neck) [57]. Similarly, in a study investigating
the efficacy of a canarypox virus-vectored FeLV vaccine (Purevax® FeLV, Merial), no
difference in vaccine efficacy was observed, whether the FeLV component was administered
as a monovalent or polyvalent vaccine [58]. Field-based vaccine efficacy studies for all
FeLV vaccines are required to determine vaccine performance under natural challenge
conditions and in different jurisdictions where different FeLV strains are circulating, similar
to studies testing the efficacy of Fel-O-Vax® FIV in the field [14,59].
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5. Conclusions
In many countries around the world, including Australia, the prevalence of FeLV
infection has decreased in part due to the use of efficacious vaccines. In other countries,
including many in Asia, South America and some parts of Europe, the prevalence of FeLV
remains high and vaccination programs are urgently required. It will be important to
determine whether the increased humoral antibody response against the FeLV SU observed
in FeLV-unexposed cats vaccinated with the monovalent FeLV vaccine (Fel-O-Vax® Lv-K)
compared to the polyvalent vaccine (Fel-O-Vax® 5) is correlated with increased efficacy,
and to address whether the site of vaccine administration affects the anti-SU antibody
response and hence the efficacy of vaccination. Encouragingly, after natural exposure
to FeLV, FeLV-vaccinated cats had comparable anti-SU antibody levels, suggesting that
vaccination with either the monovalent or polyvalent Fel-O-Vax® FeLV vaccine initiates
a strong and protective antibody response on challenge. Veterinarians should continue
to vaccinate any cat likely to be exposed to FeLV-infected cats, particularly kittens and
young adult cats in multi-cat situations, to reduce the risk of progressive FeLV infection
and the development of disease. FeLV testing prior to vaccination is advisable and will
assist studies of the efficacy of FeLV vaccination in the field.
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